Topical finasteride represents the most significant development in oral finasteride's 25-year history: the same active molecule, same mechanism, but applied directly to the scalp to reduce the systemic exposure that underlies the drug's side effect profile. It's a compelling concept with growing evidence behind it.
Quick Answer
Topical finasteride 0.25% applied once daily lowered scalp DHT by roughly 40-70% in small short-term studies, and in a phase III trial it reduced serum DHT by about 35% vs. about 56% for oral finasteride. That trial found hair count gains numerically similar to oral at 24 weeks. It is the preferred formulation for men concerned about systemic side effects.
What Is Topical Finasteride?
Topical finasteride is finasteride dissolved in a vehicle (typically ethanol, propylene glycol, or a polymer-based gel) that allows it to penetrate the scalp and act locally. The concept is to deliver high concentrations of finasteride to scalp follicles while limiting absorption into the bloodstream.
The most common formulations in clinical studies use 0.25% or 0.5% finasteride solution or gel, applied once daily. Commercial formulations (Hims, Happy Head) typically combine finasteride with minoxidil in a single topical product for convenience.
Topical finasteride is not separately FDA-approved — finasteride's approval is for the oral 1mg form only. Topical finasteride is either prescribed off-label (using compounded preparations) or through telehealth platforms that formulate their own topical products.
How Does Topical Finasteride Work?
The mechanism is identical to oral finasteride: inhibition of type II 5-alpha reductase, reducing conversion of testosterone to DHT. The difference is in where that inhibition occurs and how much drug enters the systemic circulation.
Scalp DHT Reduction
When topical finasteride is applied directly to the scalp, it achieves high local concentrations in scalp tissue — the target site for hair loss treatment. In small one-week studies, topical finasteride reduced scalp tissue DHT by roughly 40-70% depending on dose, comparable to oral finasteride's scalp DHT reduction.
Serum DHT Reduction
Because topical finasteride is not designed for maximal systemic absorption, it generally produces a lower serum DHT reduction — about 35% vs. about 56% for oral finasteride in the phase III trial. The effect is dose-dependent: small doses lowered serum DHT by only about 25% in early studies, while larger doses lowered it by 60-70%, as much as the tablet.
This is the key pharmacological distinction. Serum DHT reduction correlates with systemic exposure, which underlies sexual and hormonal side effects. By achieving adequate scalp DHT blockade with lower systemic exposure, topical finasteride aims to deliver efficacy with a reduced side effect burden.
What Does the Evidence Say?
The Caserini 2014 Studies
Dr. Mauro Caserini and colleagues conducted the foundational pharmacokinetic studies for this topical finasteride solution in the mid-2010s.
A 2014 open-label pharmacokinetic study randomized 24 men with androgenetic alopecia to topical finasteride 0.25% solution (twice daily) or the oral 1mg tablet for 7 days. Results:
- Plasma finasteride exposure was far lower with the topical solution than with the tablet
- Plasma DHT reduction was nonetheless similar: ~68-75% with topical vs. ~62-72% with oral
- A 2016 follow-up (two small 1-week randomized studies) found that lower once-daily doses still cut scalp DHT by about 47-52% while reducing serum DHT by only about 24-26%
Phase III RCT — Topical Finasteride Spray
A larger phase III, double-blind randomized trial of 458 men with androgenetic alopecia compared topical finasteride 0.25% spray once daily with placebo and with oral finasteride 1mg once daily over 24 weeks. Published in 2021-2022, this represents the most robust comparative data:
Results at 24 weeks:
- Topical finasteride increased target area hair count significantly more than placebo (+20.2 vs. +6.7 hairs)
- Hair count gains were numerically similar to oral finasteride (+21.1 hairs); the trial was not designed to formally compare topical with oral on hair count
- Serum DHT reduction: oral group ~56%, topical group ~35%
- Treatment-related sexual side effects: 2.8% topical, 3.3% placebo, 4.8% oral
The Combination Formulation Studies
Hims and similar platforms offer topical sprays combining finasteride (0.25-0.5%) with minoxidil (5%). Evidence for combination topicals is still small: a 2018 randomized, double-blind trial in 40 men found a solution of 0.25% finasteride mixed with 3% minoxidil was significantly superior to 3% minoxidil alone for hair density and diameter at 24 weeks, with only about a 5% reduction in plasma DHT.
Topical vs. Oral Finasteride
| Topical Finasteride | Oral Finasteride | |
|---|---|---|
| FDA approved for hair loss | No (off-label) | Yes (1mg) |
| Serum DHT reduction | ~35% (phase III; dose-dependent) | ~60-70% |
| Scalp DHT reduction | ~40-70% (small short-term studies) | ~60-65% |
| Hair count improvement | Comparable (24-week data) | Extensive evidence |
| Side effect profile | Lower systemic exposure; likely lower SE risk | Modest SE rate (~3-4%) |
| Long-term data | Limited | Extensive (20+ years) |
| Combined formulation | Yes (with minoxidil) | No (separate application) |
| Cost | $40-80/month (telehealth) | $20-40/month (generic) |
The Efficacy Uncertainty
The 24-week comparative data is reassuring, but a real open question remains: does the lower serum DHT reduction matter over longer timeframes?
Finasteride's benefits in long-term trials (5-year data from Merck) are cumulative — continued DHT suppression maintains and slowly builds on results. Whether topical's lower serum DHT reduction produces equivalent outcomes over 5-10 years is genuinely unknown. The honest answer is: we don't have that data yet.
For men where side effects are a primary concern, the trade-off of somewhat uncertain long-term equivalence vs. reduced systemic exposure may be entirely acceptable. For men without side effect concerns who want the most evidence-backed option, oral remains the standard.
Side Effects
Compared to Oral
Topical finasteride has less systemic exposure and lower serum DHT reduction. Clinical data so far suggests a lower likelihood of sexual side effects compared to oral, though:
- Studies to date are relatively small and short-term
- Side effects are still possible — serum DHT is still reduced (about 35% in the phase III trial), not zero
- Some users do report libido changes or sexual side effects with topical
Local Side Effects
- Scalp irritation — less common than with topical minoxidil solutions (which contain propylene glycol), but reported with some vehicle formulations
- Application site reactions — redness, dryness in some users
- The alcohol or polymer vehicles in some formulations may cause scalp dryness
Pregnancy Warning
The same contraindication applies as for oral finasteride: topical finasteride must not be used by pregnant women or women who may become pregnant, and women should not handle crushed or broken finasteride products. Men using topical finasteride who have pregnant partners should discuss safe handling with their prescriber.
Where to Get Topical Finasteride
Hims offers the most accessible and popular topical combination formulation — their finasteride/minoxidil spray is one of their top-selling products. Pricing runs approximately $40-65/month depending on formulation.
Happy Head specializes in compounded topical formulations including topical finasteride. Their formulations are physician-reviewed and can be customized. Pricing approximately $45-75/month.
Strut Health also compounds topical finasteride — prescribed and customized by physicians, either alone or combined with minoxidil and other actives. A physician consultation is required, and formulas can be tailored to your case.
Compounding pharmacies with a prescription from any physician can prepare topical finasteride. This is often the most affordable option if you have a prescriber.
See our full Hims vs. Keeps comparison for platform pricing and user experience details.
Who Is Topical Finasteride For?
Topical finasteride is the better choice for:
- Men with history of sexual side effects on oral finasteride — this is the primary clinical use case
- Men who are concerned about systemic side effects and are willing to accept some uncertainty about long-term equivalence
- Men who want a convenient single-product solution combining finasteride + minoxidil in one application
- Men trying finasteride for the first time who want to start with lower systemic exposure
Oral finasteride may still be preferred for:
- Men without side effect concerns who want the most extensively studied formulation
- Men on a tight budget — generic oral is significantly cheaper
- Men who have already been on oral finasteride without issues and don't need to switch
Our Verdict
Topical finasteride is a meaningful innovation — not a marketing repackaging of the same thing. The pharmacokinetic rationale is sound, the 24-week comparative data is encouraging, and for men where side effects are a genuine barrier to treatment, it's an important option.
The honest caveat is the long-term uncertainty: oral finasteride's 5-year and 10-year data is reassuring in ways that topical's isn't yet. If side effects aren't a concern for you, oral finasteride 1mg + topical minoxidil remains the best-evidenced protocol.
If side effects are a concern — or have been a past experience — topical finasteride is a clinically legitimate and increasingly well-evidenced alternative.
Sources
- Caserini M, Radicioni M, Leuratti C, Annoni O, Palmieri R. A novel finasteride 0.25% topical solution for androgenetic alopecia: pharmacokinetics and effects on plasma androgen levels in healthy male volunteers. International Journal of Clinical Pharmacology and Therapeutics. 2014;52(10):842-849. PMID: 25074865.
- Caserini M, Radicioni M, Leuratti C, Terragni E, Iorizzo M, Palmieri R. Effects of a novel finasteride 0.25% topical solution on scalp and serum dihydrotestosterone in healthy men with androgenetic alopecia. International Journal of Clinical Pharmacology and Therapeutics. 2016;54(1):19-27. PMID: 26636418.
- Piraccini BM, Blume-Peytavi U, Scarci F, et al. Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial. Journal of the European Academy of Dermatology and Venereology. 2022;36(2):286-294. PMID: 34634163.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative efficacy of minoxidil and the 5-alpha reductase inhibitors in androgenetic alopecia treatment of male patients: a network meta-analysis. JAMA Dermatology. 2022;158(3):266-274. PMID: 35107565.
- Lee SW, Juhász M, Mobasher P, Ekelem C, Mesinkovska NA. A systematic review of topical finasteride in the treatment of androgenetic alopecia in men and women. Journal of Drugs in Dermatology. 2018;17(4):457-463. PMID: 29601622.
- Suchonwanit P, Srisuwanwattana P, Chalermroj N, Khunkhet S. A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil vs. 3% minoxidil solution in the treatment of male androgenetic alopecia. Journal of the European Academy of Dermatology and Venereology. 2018;32(12):2257-2263. PMID: 29972712.
- Drake L, Hordinsky M, Fiedler V, et al. The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia. Journal of the American Academy of Dermatology. 1999;41(4):550-554. PMID: 10495374.